Trial · NCT02704403
Adverse events596
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 596
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Diarrhoea | Gastrointestinal disorders | 120 mg Elafibranor | 148 | 1,433 | 171 |
| other | Diarrhoea | Gastrointestinal disorders | Placebo | 68 | 717 | 82 |
| other | Nausea | Gastrointestinal disorders | 120 mg Elafibranor | 140 | 1,433 | 158 |
| other | Nausea | Gastrointestinal disorders | Placebo | 50 | 717 | 51 |
| other | Abdominal pain upper | Gastrointestinal disorders | 120 mg Elafibranor | 83 | 1,433 | 105 |
| other | Abdominal pain upper | Gastrointestinal disorders | Placebo | 47 | 717 | 49 |
| other | Abdominal pain | Gastrointestinal disorders | 120 mg Elafibranor | 79 | 1,433 | 94 |
| other | Abdominal pain | Gastrointestinal disorders | Placebo | 49 | 717 | 57 |
| other | Fatigue | General disorders | 120 mg Elafibranor | 103 | 1,433 | 111 |
| other | Fatigue | General disorders | Placebo | 49 | 717 | 54 |
| other | Urinary tract infection | Infections and infestations | 120 mg Elafibranor | 145 | 1,433 | 236 |
| other | Urinary tract infection | Infections and infestations | Placebo | 77 | 717 | 134 |
| other | Nasopharyngitis | Infections and infestations | 120 mg Elafibranor | 134 | 1,433 | 186 |
| other | Nasopharyngitis | Infections and infestations | Placebo | 52 | 717 | 61 |
| other | Influenza | Infections and infestations | 120 mg Elafibranor | 115 | 1,433 | 127 |
| other | Influenza | Infections and infestations | Placebo | 54 | 717 | 68 |
| other | Upper respiratory tract infection | Infections and infestations | 120 mg Elafibranor | 107 | 1,433 | 132 |
| other | Upper respiratory tract infection | Infections and infestations | Placebo | 46 | 717 | 55 |
| other | Bronchitis | Infections and infestations | 120 mg Elafibranor | 93 | 1,433 | 111 |
| other | Bronchitis | Infections and infestations | Placebo | 33 | 717 | 36 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02704403/events